Kedrion
Kedrion Biopharma, commonly referred to as Kedrion, is a leading global player in the biopharmaceutical industry, headquartered in Italy. Founded in 2001, the company has established a strong presence in major operational regions, including Europe and North America, focusing on the development and production of human plasma-derived therapies. Kedrion's core offerings include immunoglobulins, clotting factors, and albumin, which are essential for treating various medical conditions. What sets Kedrion apart is its commitment to quality and innovation, ensuring that its products meet the highest safety standards. With a robust market position, Kedrion has achieved significant milestones, including expanding its product portfolio and enhancing its global distribution network, solidifying its reputation as a trusted provider in the biopharmaceutical sector.
DitchCarbon Score
How does Kedrion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kedrion's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kedrion's reported carbon emissions
In 2022, Kedrion reported total carbon emissions of approximately 66,342,000 kg CO2e, comprising 30,122,000 kg CO2e from Scope 1 emissions and 35,982,000 kg CO2e from Scope 2 emissions. This marked a significant increase from 2021, where emissions were about 42,751,000 kg CO2e, with 16,894,000 kg CO2e from Scope 1 and 25,581,000 kg CO2e from Scope 2. Kedrion has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of Scope 3 emissions data indicates a potential area for future reporting and improvement. The company is headquartered in Italy and operates within the biopharmaceutical industry, which is increasingly focusing on sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 2,421 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kedrion is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
